1 / 37

Menopause and HRT

Menopause and HRT. Maureen Mc Farland October 2006. Consultation. Ascertain menopausal status (LMP, symptoms, contraception) Risk factors for CVD / VTE Risk factors for osteoporosis / breast Ca Woman’s personal views on the menopause itself and on any interventions

adamma
Download Presentation

Menopause and HRT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Menopause and HRT Maureen Mc Farland October 2006

  2. Consultation • Ascertain menopausal status (LMP, symptoms, contraception) • Risk factors for CVD / VTE • Risk factors for osteoporosis / breast Ca • Woman’s personal views on the menopause itself and on any interventions • It is a woman’s evidence-based patient choice to take or not to take HRT/ therapy • Her decision recorded

  3. Menopause in perspective • Average age – 52 • Average life expectancy – 81 and increasing • women can expect to live around 30 years in the postmenopausal state • More women will live to be 100 • Can now be considered to be a mid-life event

  4. Symptoms: vasomotor • About 70% in Western cultures will experience vasomotor symptoms • Prevalence highest in 1st year after FMP • Sympathetic nervous control of blood flow to the skin is impaired • No reflex constriction to ice stimulus • Serotonin and its receptors implicated

  5. Symptoms : psychological • While many symptoms have been associated with menopause • General population studies show most women do not experience major changes in mood • Likely to be associated with past problems and current life stresses

  6. Symptoms: sexual dysfunction • US National Health & Social Life Survey : - SD is more prevalent for women (43%) than men (31%) • Population studies: numbers with FSD rise from 42% to 88% during early to late perimenopause (before FMP) • Underlying reasons for FSD are commonly multifactorial – hormonal and non-hormonal

  7. Long term complications of oestrogen deficiency • Greater bearing on women’s QOL • Clinically silent for years • Far greater problem in terms of morbidity, mortality and economic burden - Osteoporosis • CVD • Dementia • Urogenital atrophy

  8. Osteoporosis • 1 in 3 women, 1 in 12 men • National Institute of Health definition: - skeletal disorder characterized by compromised bone strength predisposing to increased risk of fracture • Bone strength: integration of bone density and bone quality

  9. Determinants of bone mass: • Age – peaks mid 20s, - begins to decline mid-40s - accelerated rate of loss for 6-10 yrs after menopause - slower rate of loss - Seems sensible to encourage good diet in childhood, with exercise and no smoking – little evidence of efficacy of these

  10. Determinants of bone mass • Ethnicity and genetic factors – greater role than environmental influences • DMPA – relationship complex: • Amenorrhoea is associated with a 5-10% loss of bone – not progressive • Patient’s own risk factors for OP • Should be stopped around 40 • Long term effects on teenagers uncertain

  11. Risk factors for osteoporosis • Genetic – FH esp 1° relative with hip • Constitutional – low BMI, early menopause • Environmental – smoking, alcohol, diet, sedentary • Drugs – steroids • Diseases – RA, neuromuscular,liver disease, malabsorption, hyperparathyroid, hyperthyroid, hypogonadism

  12. Cardiovascular disease • Most common cause of death in women over 60yrs • Stroke – major cause of long term disability • Oophorectomized women are at 2-3 fold increase risk of CHD

  13. WHI (nearly 4 yrs ago) • Reported no beneficial effect and may increase the risk of CHD • BUT >20% of these women were >70yrs, mean age 63yrs • NOT age of typical menopausal woman with symptoms • WHI data overall cannot be used to discuss women <60yrs • WHI 50-59 – less CHD, CABG, PCTA, angina

  14. Danish Study • 30% decrease in mortality from CHD • Interpretation: there may be a window of opportunity for CVD protection • No comment from regulating authorities

  15. Dementia • One of the major causes of disability world-wide • Women have a central role providing care and support to people with dementia • Swedish twin study 2005 (6604) • Length of reproductive period and age at menopause were inversely associated with risk of cognitive decline • Use of HT -> 40% decline in risk

  16. Urogenital Atrophy • Oestrogen deficiency after menopause cause atrophic changes in urogenital tract -> urinary symptoms eg frequency, nocturia, incontinence, recurrent infection. • These may co-exist with symptoms of genital atrophy – dyspareunia, itching, burning, dryness • Smoking decreases bioavailability of oestrogen -> inc symptoms • Timing of symptoms varies

  17. Vaginal atrophy • Pre-menopausal vaginal epithelium pH <4 • Post-menopausal – glycogen depletion -> loss of lactic acid-> vaginal more easily colonised by other bacteria • Changes in collagen in pelvic floor -> pelvic floor atrophy and shortened urethra • Women using systemic HT may need additional vaginal oestrogen

  18. Identify the “at risk” patients • Young women with premature menopause • hormone profile in all hysterectomised women • women with fragility fractures • Integrated care within a practice - include Practice nurses doing “well-woman” clinics • discharge letters from hospital

  19. examination • BMI • BP • Breast and pelvic examination ONLY if clinically indicated (as with OCP) • Encourage cervical and breast screening

  20. HRT Prescribing • Risk / benefit analysis

  21. Follow-up • 3 months - symptom relief, - persistence of s/es - abnormal bleeding - (BP) • Yearly - risk / benefit discussion - BP - abnormal bleeding

  22. Investigations • FSH levels are only helpful if diagnosis is in doubt • FSH not a guide to fertility status • FSH no help in monitoring HRT • Measure FSH if suspected premature Ov failure • Sample FSH ASAP after day 1 • Oestradiol levels only useful for monitoring non-oral HRT

  23. Investigations • TFT – abnormalities can be confused with menopausal symptoms • Urinary catecholamines – rare cause of hot flushes • Total testosterone unhelpful (Most bound to SHBG [2/3] or albumin [1/3] ) • Free testosterone index not available routinely

  24. Investigations • Mammography: no evidence supports routine, over and above NHSBSP • Only 1 in 4 women on combined HRT showed increase breast density • Increase was 3%-6% • MWS – observational data from uncontrolled trials – increase interval cancers • WHI O-only arm – NO increased Ca risk

  25. Side effects and Risks • Oestrogen-related: fluid retention, bloating, breast tenderness, nausea, headaches, leg cramps, dyspepsia • Progestogen-related: fluid retention, breast tenderness, headaches or migraine, mood swings, depression, acne, lower abdominal pain, backache

  26. Weight gain? • Major reason given why women are reluctant to try HRT • BUT • Randomized placebo-controlled trials repeatedly show no evidence of HRT – induced weight gain! • Oestrogen deficiency alters fat metabolism -> increased male distribution of fat deposition

  27. Abnormal vaginal bleeding • With sequential – change in pattern or BTB • CCT – persists > 4-6 months • Concordance, other medication • Examine, cervical cytology / Chlamydia • TVS – endometrium > 4 mm – endometrial biopsy / hysteroscopy

  28. HRT and risk of VTE • HRT is associated with significant (but small ) increased risk of thrombosis & stroke • Possibly worse in first years of treatment • No increase with transdermal oestrogen • If high risk for VTE – consider transdermal eg women with BMI >30,

  29. WHI data (average age 63yrs) • Extra 7 CHD events per 10,000 • Extra 8 strokes per 10,000 • Extra 8 breast cancers per 10,000 • Extra 18 VTE per 10,000 • 5 less hip fractures per 10,000 • 6 less colorectal Ca per 10,000 • total mortality - no significant difference

  30. Breast Cancer data • Breast cancers from age 50 - 70 /1000 women time on HRT Breast Cancers extra Ca never 45 per 1000 - 5 years use 47 per 1000 2 / 1000 10 yrs. use 51 per 1000 6 / 1000 15 yrs. use 57 per 1000 12 / 1000 Beral et al Lancet 1997

  31. WHI breast Ca risk data for 5 years use per 1000 women • Increase only seen in combined therapy • Age absolute difference in risk (death) 50-59 +3 (+1.4) 60-69 +4 (+1.5) 70-79 +7 (+2.2) All +4 (+1.8)

  32. Osteoporosis • Clear evidence of reduced hip and spinal fracture risk with lower doses • Long-term treatment needed for ongoing fracture prevention • Regulatory authorities Dec 2003: HRT not to be used as a first line prevention • Alternatives are available for prevention and treatment in older women • Oestrogen - best option in women who are younger or symptomatic or both

  33. Osteoporosis • NICE guidelines next year • Calculation of 10 year fracture risk • Cost of achieving gain in QALY • Focus is moving away from prevention, and towards older age groups • (GP contract has failed to reward OP management)

  34. Osteoporosis • Anti-resorptive agents – oestrogen, SERMs, Bisphosphonates, calcitrol, calcitonin • Anabolic agents – Teriparatide ( pulsed subcutaneous administration parathyroid hormone) • Dual action – strontium (Protelos) • Women >65 who show unsatisfactory response to bisphosphonates – PTH • (osteonecrosis of jaw – seen in high dose bisphosphonates used to treat Ca)

  35. Summary • Decision making is based on Negotiation • indication should dictate the duration • HRT remains treatment of choice for relief of symptoms and early prevention of Osteoporosis • Switch to period - free once clearly postmenopausal • Lower dose preparations are better tolerated

  36. Summary • indications for longterm (> 10 yrs.)HRT: -continuing symptoms - benefits outweigh risks -no alternative for osteoporosis • reassess individual risks regularly in light of changing personal circumstances and new data

  37. Women in the Autumn of their lives deserve an Indian Summer, rather than a Winter of Discontent Robert Greenblatt

More Related